Long-Term Response to 177 Lu-DOTATATE in Localised Head and Neck Paraganglioma: A Retrospective Single-Centre Study (EANM 2026) - Sep 29, 2026 - Abstract #EP-0868; "177Lu-DOTATATE demonstrated durable disease control and a favourable safety profile, with 97.4% of patients progression-free after prolonged follow-up and most showing measurable tumour reduction. Baseline SSTR expression may predict morphological response. These findings support PRRT as a valuable treatment option for localised HNPGLs, particularly where conventional therapies carry substantial morbidity."
Retrospective data • Hematological Malignancies • Neuroendocrine Tumor • Solid Tumor • SSTR
|
|
G. Ferreira 1, 2; J. Ferro 2; A. Santos 2; I. Azevedo 2; C. Sanches 2; L. Giesteira 2; P. Antunes 2; E. Monteiro 2; I. L. Sampaio 2
|